TISIDB

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Cytoplasm Note=Only a small amount appears to be present at the cell surface (PubMed:17145755).
Domain	PF12947 EGF domain PF02469 Fasciclin domain PF00193 Extracellular link domain
Function	Phosphatidylserine receptor that enhances the engulfment of apoptotic cells. Hyaluronan receptor that binds to and mediates endocytosis of hyaluronic acid (HA). Acts also, in different species, as a primary systemic scavenger receptor for heparin (Hep), chondroitin sulfate (CS), dermatan sulfate (DS), nonglycosaminoglycan (GAG), acetylated low-density lipoprotein (AcLDL), pro-collagen propeptides and advanced glycation end products (AGE). May serve to maintain tissue integrity by supporting extracellular matrix turnover or it may contribute to maintaining fluidity of bodily liquids by resorption of hyaluronan. Counter receptor which plays an important role in lymphocyte recruitment in the hepatic vasculature. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection. The proteolytically processed 190 kDa form also functions as an endocytosis receptor for heparin internalisation as well as HA and CS.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0006022 aminoglycan metabolic process GO:0006026 aminoglycan catabolic process GO:0006027 glycosaminoglycan catabolic process GO:0006898 receptor-mediated endocytosis GO:0007596 blood coagulation GO:0007599 hemostasis GO:0030193 regulation of blood coagulation GO:0030203 glycosaminoglycan metabolic process GO:0030212 hyaluronan metabolic process GO:0030214 hyaluronan catabolic process GO:0042742 defense response to bacterium GO:0048514 blood vessel morphogenesis GO:0050817 coagulation GO:0050818 regulation of coagulation GO:0050878 regulation of body fluid levels GO:0061041 regulation of wound healing GO:0098542 defense response to other organism GO:1900046 regulation of hemostasis GO:1901136 carbohydrate derivative catabolic process GO:1901565 organonitrogen compound catabolic process GO:1903034 regulation of response to wounding GO:1903510 mucopolysaccharide metabolic process
Molecular Function	GO:0005041 low-density lipoprotein receptor activity GO:0005044 scavenger receptor activity GO:0005539 glycosaminoglycan binding GO:0005540 hyaluronic acid binding GO:0015035 protein disulfide oxidoreductase activity GO:0015036 disulfide oxidoreductase activity GO:0016667 oxidoreductase activity, acting on a sulfur group of donors GO:0030169 low-density lipoprotein particle binding GO:0030228 lipoprotein particle receptor activity GO:0038024 cargo receptor activity GO:0071813 lipoprotein particle binding GO:0071814 protein-lipid complex binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030666 endocytic vesicle membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-2142845: Hyaluronan metabolism R-HSA-2160916: Hyaluronan uptake and degradation R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates R-HSA-3000497: Scavenging by Class H Receptors R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between STAB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of STAB2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of STAB2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.064	0.693
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.103	0.836
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.186	0.639
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.098	0.0628
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.68	0.735
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.629	0.506
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.253	0.672
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.082	0.926
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.371	0.7
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.688	0.294
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.599	0.0595
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.98	0.02

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of STAB2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	25.9	17.8	8.1	0.404
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	21.4	-21.4	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	25.9	16.9	9	0.386
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	28.6	11.8	16.8	0.257
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	37.5	0	37.5	0.209
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	18.2	4.9	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	15.8	3.7	12.1	0.224
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	25	0	25	0.103
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STAB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STAB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STAB2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STAB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of STAB2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between STAB2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	STAB2
Name	stabilin 2
Aliases	DKFZP434E0321; FELL; STAB-2; HARE; FEEL-2; hyaluronic acid receptor for endocytosis; FEEL2; FELE-2; FELL2; F ......
Chromosomal Location	12q23.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting STAB2 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting STAB2.

ID	Name	Drug Type	Targets	#Targets
DB08818	Hyaluronic acid	Small Molecule	C1QBP, CD44, HABP2, HABP4, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, IM ......	15

Browse STAB2